依从性差的患者接受无意的长效卡帕韦单药治疗实现HIV病毒抑制：病例系列
HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series.
作者信息
Mehtani Nicky J, Grochowski Janet, Chimezie Anthonia, Strough Alix, Strieff Sarah, Gandhi Monica
机构信息
Division of General Internal Medicine, University of California, San Francisco, San Francisco, California, USA.
Whole Person Integrated Care, San Francisco Department of Public Health, San Francisco, California, USA.
出版信息
Open Forum Infect Dis. 2025 Jun 11;12(6):ofaf330. doi: 10.1093/ofid/ofaf330. eCollection 2025 Jun.
Abstract
Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9-38 weeks, highlighting its potential among adherence-challenged populations.
摘要
来那卡帕韦是一种长效人类免疫缺陷病毒（HIV）衣壳抑制剂，根据目前有限的数据，其耐药性屏障被认为较低。我们描述了4例患有严重精神疾病的无家可归患者，他们在无意之中接受了9至38周的来那卡帕韦单药治疗，但仍保持了HIV抑制（<30拷贝/毫升），突出了该药在依从性差的人群中的潜力。
相似文献
1
HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series.依从性差的患者接受无意的长效卡帕韦单药治疗实现HIV病毒抑制：病例系列
Open Forum Infect Dis. 2025 Jun 11;12(6):ofaf330. doi: 10.1093/ofid/ofaf330. eCollection 2025 Jun.
2
Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.乌干达艾滋病毒感染者结核病预防治疗期间减少饮酒和提高异烟肼依从性的经济激励措施：一项开放标签、析因随机对照试验。
Lancet Glob Health. 2023 Dec;11(12):e1899-e1910. doi: 10.1016/S2214-109X(23)00436-9.
3
Point-of-care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities.在医疗机构就诊的 HIV 感染者/艾滋病患者中，使用即时病毒载量检测发现病毒载量高。
Cochrane Database Syst Rev. 2022 Mar 10;3(3):CD013208. doi: 10.1002/14651858.CD013208.pub2.
4
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.用于治疗符合抗逆转录病毒治疗条件的孕妇艾滋病毒感染的抗逆转录病毒疗法。
Cochrane Database Syst Rev. 2010 Mar 17(3):CD008440. doi: 10.1002/14651858.CD008440.
5
Accuracy of measures for antiretroviral adherence in people living with HIV.抗逆转录病毒药物依从性测量在 HIV 感染者中的准确性。
Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD013080. doi: 10.1002/14651858.CD013080.pub2.
6
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study.在东非、中非、南非和西非，对接受多替拉韦、拉米夫定和替诺福韦治疗但病毒载量持续未被抑制的成人HIV感染者抗逆转录病毒治疗方案转换选择的评估：一项模型研究
Lancet HIV. 2025 Jun 24. doi: 10.1016/S2352-3018(25)00068-2.
7
Antihelminthics in helminth-endemic areas: effects on HIV disease progression.蠕虫流行地区的抗蠕虫药物：对HIV疾病进展的影响。
Cochrane Database Syst Rev. 2016 Apr 14;4(4):CD006419. doi: 10.1002/14651858.CD006419.pub4.
8
Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.用于治疗HIV感染的三联或四联与二联抗逆转录病毒维持治疗方案
Cochrane Database Syst Rev. 2003(4):CD002037. doi: 10.1002/14651858.CD002037.
9
Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.职业性HIV暴露后的抗逆转录病毒暴露后预防（PEP）。
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002835. doi: 10.1002/14651858.CD002835.pub3.
10
Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review.艾滋病毒/艾滋病感染者的住房状况、医疗保健及健康结果：一项系统综述
Am J Public Health. 2016 Jan;106(1):e1-e23. doi: 10.2105/AJPH.2015.302905. Epub 2015 Nov 12.
本文引用的文献
1
HIV Viral Suppression With Use of Long-Acting Antiretroviral Therapy in People With and Without Initial Viremia.在有和没有初始病毒血症的人群中使用长效抗逆转录病毒疗法实现HIV病毒抑制
JAMA. 2025 Apr 22;333(16):1451-1453. doi: 10.1001/jama.2025.0109.
2
Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years.新型HIV衣壳抑制剂来那卡帕韦治疗两年后，对大量接受过多种治疗的HIV感染者的耐药性分析
J Infect Dis. 2025 Jan 28. doi: 10.1093/infdis/jiaf050.
3
Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis.长效卡博特韦用于HIV治疗的病毒学失败及整合酶链转移抑制剂药物耐药性的出现：一项荟萃分析。
Clin Infect Dis. 2024 Dec 26. doi: 10.1093/cid/ciae631.
4
Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial Viremia.初始病毒血症的HIV感染者开始使用长效卡博特韦/利匹韦林治疗48周时的病毒抑制率
Clin Infect Dis. 2025 Apr 30;80(4):864-870. doi: 10.1093/cid/ciae500.
5
Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.使用长效组合药物来那卡帕韦和卡博特韦治疗的HIV感染者病例系列：呼吁进行一项试验。
Open Forum Infect Dis. 2024 Apr 16;11(4):ofae125. doi: 10.1093/ofid/ofae125. eCollection 2024 Apr.
6
Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel.美国国际艾滋病学会（IAS-USA）指南小组关于使用卡博特韦和利匹韦林治疗HIV感染者的最新治疗建议
JAMA. 2024 Mar 26;331(12):1060-1061. doi: 10.1001/jama.2024.2985.
7
Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People Experiencing Homelessness.在有 homelessness 经历的人群中实施一项低门槛长效注射型抗逆转录病毒治疗和预防计划的可行性。
J Acquir Immune Defic Syndr. 2024 May 1;96(1):61-67. doi: 10.1097/QAI.0000000000003396.
8
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.长效卡博特韦和rilpivirine的真实世界谷浓度及有效性：瑞士的一项多中心前瞻性观察研究
Lancet Reg Health Eur. 2023 Dec 13;36:100793. doi: 10.1016/j.lanepe.2023.100793. eCollection 2024 Jan.
9
Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV.长效抗逆转录病毒疗法在不同 HIV 人群中的示范项目。
Ann Intern Med. 2023 Jul;176(7):969-974. doi: 10.7326/M23-0788. Epub 2023 Jul 4.
10
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.利纳卡帕韦治疗多种药物耐药 HIV-1 感染时对衣壳的抑制作用。
N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542.
Zotero 插件